The population of health economic models is critical

Bone

Volumn 43, Issue 1, 2008, Pages 214-

  Stevenson, Matt ^a  

^a NONE

Author keywords

Health economics; Mass Screening; NICE; Osteoporosis; Quality of Life

Indexed keywords

ALENDRONIC ACID;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FRACTURE; HEALTH ECONOMICS; LETTER; MODEL; MORTALITY; POPULATION; PRIMARY PREVENTION; SCREENING;

ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; FEMALE; FRACTURES, BONE; HUMANS; MODELS, ECONOMIC;

EID: 44949231162     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.02.018     Document Type: Letter

References (3)

1. Kanis J.A., Adams J., Borgstrom F., Cooper C., Jonsson B., Preedy D., Selby P., and Compston J. The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2007) 10.1016/j.bone.2007.10.019
2. Delmas P.D., and Siris E.S. NICE recommendations for the prevention of osteoporatic fractures in postmenopausal women. Bone 42 (2008) 16-18
3. Stevenson M.D., Brazier J.E., Calvert N.W., Lloyd-Jones M., Oakley J., and Kanis J.A. Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. Journal of Operational Research Society 56 2 (2005) 214-221